Adrian Mills (Novimmune S.A.)

Mills, Adrian (Novimmune 201409– CBO before GSK since 2000)

	Organisation	Novimmune S.A.
	Former/major organisation	GlaxoSmithKline plc (LSE: GSK, NYSE: GSK)
	Today	GSK plc (LSE: GSK, NYSE: GSK)
	Group	GSK (Group)
	Product	NI-0101 (Novimmune)
	Product 2	emapalumab (NI-0501)

Record changed: 2019-06-09

Picture EBD Group World of Partnering Opportunities 650x200px

More documents for Adrian Mills

[1] Novimmune S.A.. (3/27/17). "Press Release: Novimmune Opens a Branch Office in Basel". Geneva & Basel....
[2] Novimmune S.A.. (2/13/17). "Press Release: Novimmune and LegoChem Biosciences Enter Research Collaboration on Antibody Drug Conjugate". Geneva....
[3] Novimmune S.A.. (1/4/17). "Press Release: Novimmune Grants Tiziana an Exclusive License to NI-1201, an anti-IL-6R Monoclonal Antibody for the Treatment of Autoimmune and Inflammatory Diseases". Geneva....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]